Showing papers by "Joanne M. Meyer published in 2010"

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

Abstract: Charles Paulding and colleagues report a genome-wide association study for susceptibility to lumiracoxib-induced liver injury. The study utilized lumiracoxib-treated cases with liver injury and lumiracoxib-treated controls, and included independent replication. The authors identify an association to a common HLA haplotype.

Biomarkers related to age-related macular degeneration (amd)

Abstract: A method of determining the therapeutic outcome of treating an AMD patient with an AMD therapeutic agent is provided. The method includes obtaining a sample from the patient, and analyzing the sample to determine the existence of one or more biomarkers associated with an improved response to treatment with the AMD therapeutic agent.

OC-036 A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

Abstract: Introduction Lumiracoxib is a selective COX-2 inhibitor that was developed for the symptomatic treatment of osteoarthritis and acute pain. Concerns over liver injury, primarily at chronic doses >100 mg once daily, led to the withdrawal of lumiracoxib in most major drug markets worldwide. A genome-wide association study was performed to identify genetic markers associated with lumiracoxib-related liver injury. Methods Using DNA (n=10 057) collected during the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), a multistaged case-control pharmacogenetic study was conducted to identify genetic markers associated with the risk of developing elevations of liver aminotransferases (ALT/AST) during treatment with lumiracoxib. TARGET was a 52-week, gastrointestinal clinical safety outcomes study which demonstrated that lumiracoxib (400 mg once daily) reduced the risk of a definite or probable upper GI ulcer complication by 79% compared to NSAIDs (naproxen 500 mg twice daily and ibuprofen 800 mg three times daily) in non-aspirin treated osteoarthritis patients. Results Several single nucleotide polymorphisms (SNPs) from the MHC class II region on chromosome 6 were found to be associated with liver aminotransferase elevations five times the upper limit of normal (>5×ULN) in patients treated with lumiracoxib (top SNP p=2.8E-10). These findings were replicated in an independent set of patients with elevated aminotransferases (>3×ULN) (top SNP p=4.4E-12). To further refine the association results, HLA genotyping and analysis were conducted and a very strong association was identified (top HLA allele p=6.8E-25). Conclusion The study described here identified a highly significant association between HLA alleles and lumiracoxib-related liver injury. These results offer the potential to improve the safety profile of lumiracoxib by excluding patients at elevated risk for developing liver injury.

Biomarqueurs associés à la dégénérescence maculaire liée à l'âge (dmla)

Abstract: La presente invention concerne un procede permettant de determiner l'issue therapeutique d'un traitement impliquant un agent therapeutique efficace contre la DMLA chez un patient souffrant de DMLA. Ce procede comprend les etapes consistant a prelever un echantillon sur le patient et a analyser l'echantillon a la recherche d'un ou plusieurs biomarqueurs associes a une reponse amelioree au traitement impliquant ledit agent therapeutique efficace contre la DMLA.